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1. Introduction 
Breast cancer is the most prevalent cancer in women. Although the survival rate of breast 
cancer has improved steadily in the past two decades, over 40,000 women die from breast 
cancer related complications each year. The heterogeneity of breast cancer makes the 
treatment of different subtypes difficult (Gonzalez-Angulo et al., 2007; Perez et al., 2010). 
Triple negative breast cancer (TNBC) is one of the subtypes. It is negative for both estrogen 
and progesterone hormone receptors and lack the overexpression of human epidermal 
growth factor receptor 2 (HER2). TNBC constitutes approximately 15% of all breast cancers. 
However, its death rate is disproportionately higher than any other subtype of breast cancer, 
especially among young Black, Asian and Hispanic patients (Anders and Carey, 2009; 
Kassam et al., 2009; Rahman et al., 2009). Although, HER2 antibody, Herceptin, estrogen 
receptor antagonist, and aromatase inhibitor have brought hope to breast cancer patients, 
the treatment of TNBC remains to be a great challenge (Amir et al., 2010; Gluz et al., 2009; 
Silver et al., 2010). Thus it is imperative to investigate effective therapeutic targets for TNBC 
patients. 
FZD7, a Wnt pathway receptor, is one of the most abundant Frizzled family proteins 
expressed in TNBC and its cell lines. Wnt canonical signaling regulates cell fate decision 
throughout embryonic development and is related to human disease (Clevers, 2006; 
MacDonald et al., 2009; Reya and Clevers, 2005). Activation of Wnt canonical pathway is 
transduced through Frizzled (FZD) family receptors and LRP5/LRP6 coreceptor to the β-
catenin signaling cascade (Bhanot et al., 1996; Pinson et al., 2000). In the presence of canonical 
Wnt signal, FZD binds to Dishevelled (DVL) and LRP5/6 to AXIN-FRAT to form a complex. 
β-catenin is protected from phosphorylation (Tolwinski et al., 2003) and the stabilized β-
catenin translocates from the cytoplasm to the nucleus to activate the transcription of Wnt 
responsive genes by binding with T-cell factor/lymphoid enhancer factor (TCF/LEF) family 
transcription factors. Activation of these tissue-specific Wnt target genes is involved in the 
development of human tumors, including breast, colon, and other cancers (Jones and Kemp, 
2008; Lee et al., 1995; Ojalvo et al., 2010).  
To investigate the therapeutic targets for TNBC, microarray has been performed to identify 
the genes that may be involved in the tumorigenesis of TNBC. FZD7 is differentially 
expressed in TNBC which raises the possibility that aberrant Wnt signaling might be critical 
for TNBC development. In this chapter we will address the role that FZD7 plays in cell 
proliferation of TNBC and its mechanism. 
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2. FZD7 plays a critical role in cell proliferation of TNBC 
Basal-like breast cancer is categorized as TNBC because almost all basal-like breast cancers 
do not have hormone receptor expression and HER2 overexpression (Perou et al., 2000; 
Sotiriou et al., 2003). Although aberrant Wnt signaling activation has been observed in breast 
cancer (Brown, 2001; Turashvili et al., 2006), the correlation of Wnt signaling with TNBC has 
rarely been investigated. However, canonical Wnt pathway activation in basal-like tumor 
has been observed (DiMeo et al., 2009; Lindvall et al., 2009). Recently, we performed Human 
Gene Array ST-1.0 (Affymetrix) in 19 breast tumor samples of five triple negative and 14 
non-triple negative breast cancers (non-TNBC). Identification of the differentially expressed 
genes was carried out under the criteria of 1.5 fold up-regulated in TNBC with p-value less 
than 0.01. FZD7 as well as other two Wnt pathway genes were found to be overexpressed in 
TNBC tissues. Among these genes, FZD7 showed the greatest change as compared to other 
genes (Table 1).  Although other Frizzled, such as FZD3 and FZD5 showed high level 
expression in TNBC tissues, it was not significantly higher (p>0.05). This result suggested 
that overexpression of FZD3 and FZD5 in the TNBC samples used in our microarray study 
may have been due to the variation of individual samples, but not from overall upregulation 
of FZD3 and FZD5 in TNBC.  
 
Log2Ratio P-value Symbol Description Chromosome GenBank 
1.30663 0.0023467 FZD7 
frizzled homolog 7 
(Drosophila) 
2 NM_003507 
1.07657 0.0047925 TCF7 
transcription factor 7 (T-
cell specific, HMG-box) 
5 NM_003202 
0.866995 0.0083258 LRP6 
low density lipoprotein 
receptor-related protein 6
12 NM_002336 
Table 1. FZD7 and other Wnt pathway genes were up-regulated in TNBC. 
2.1 FZD7 is up-regulated in TNBC and its derived cell lines 
Aberrant Wnt signaling in TNBC has been noted by a few research groups. Dr. Bu and his 
team reported that LRP6 overexpression is found in a subtype of breast tumor that is ER-
negative and Her2-negative (Liu et al., 2010). This is consistent with our microarray result. 
Benefiting from free access to the public database, we analyzed FZD7 expression in a larger 
human breast tumor cohort study reported by Finak et al (20). We found that FZD7 mRNA 
expression was significantly higher in the TNBC samples (n=14) as compared to non-TNBC 
samples (n=109; P=0.0017, Wilcoxon Test) (Figure 1A). We further evaluated the FZD7 
expression using breast tumor tissues. In Fig 1B, the overexpression of FZD7 was observed 
in all TNBC samples, whereas the other four non-TNBC tissues with equal 
differentiation/stage minimally expressed FZD7. To validate the FZD7 overexpression in 
TNBC, immunohistochemistry staining was performed in 20 formalin-fixed paraffin-
embedded breast tumor slides. It was found that 67% of TNBC expressed FZD7; while only 
5% non-TNBC weakly expressed FZD7 (Fig. 1C). FZD7 expression in various breast cancer 
cell lines was also assessed (Fig. 1D). Among the seven cell lines investigated, MDA-MB-231 
and BT-20 cell lines expressed high levels of FZD7, while the other five cell lines either had 
no or limited FZD7 expression. While the MDA-MB-231 and BT-20 cell lines were known to 
be TNBC-derived, all other cell lines were either derived from normal breast tissue (MCF 
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10A) or non-TNBC tissues. Notably, FZD7 is the most abundant FZD in TNBC cell lines: 
MDA-MB-231 and BT-20 (Fig. 1E). 
 
 
Fig. 1. FZD7 expression in TNBC tissues and TNBC cell lines. 
2.2 FZD7shRNA suppressed tumor transformation in TNBC cell lines MDA-MB-231 
and BT-20  
To evaluate the function of FZD7 in TNBC cells, FZD7shRNA or its control GFPshRNA 
lentivirus were transduced into TNBC-derived cell lines MDA-MB-231 and BT-20, and were 
selected with puromycin. Effective knockdown of FZD7 in MDA-MB-231 and BT-20 cells 
was found in FZD7shRNA lentivirus transduced cells. It was observed that FZD7 expression 
was reduced by 95% to 97.5% at the mRNA level (Fig.23A, left panel) and almost completely 
inhibited the protein expression (Fig. 2A, right panel). Specific inhibition of FZD7 expression 
without affecting the other members of the FZD family was confirmed by RT-PCR in MDA-
MB-231(Fig. 2B) and in BT-20 cells (Fig. 2C).  
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Fig. 2. FZD7 knockdown in MDA-MB-231 and BT-20 cells. 
2.2.1 FZD7 is required for cell growth in TNBC cells 
Frizzled family gene is commonly up-regulated in various tumors from different organs. 
Wnt signaling initiated from these genes induce acceleration of cell growth in these tumor 
cells.  Comparisons were made with regards to the rate of cell growth of FZD7shRNA and 
GFPshRNA lentivirus infected MDA-MB-231 cells. As shown in Fig. 3 left panel, cell growth 
significantly slowed in FZD7shRNA transduced MDA-MB-231 cells as compared to that of 
GFPshRNA infected MDA-MB-231 cells. When both cell lines were treated with FZD7 
ligand Wnt3a, significant cell growth acceleration was observed in GFPshRNA transduced 
MDA-MB-231 cells. However, there was no growth advantage seen in FZD7shRNA 
transduced MDA-MB-231 cells. To determine if the FZD7shRNA alone is sufficient for the 
growth inhibition, MDA-MB-231/GFPshRNA cells and MDA-MB-231/FZD7shRNA cells 
were treated with LRP6 inhibitor DKK1 to block the LRP6 signal. As indicated in Fig 3 right 
panel, there is no significant change in the suppression of cell growth by double treatment 
with FZD7shRNA and DKK1 as compared with FZD7shRNA treatment alone in MDA-MB-
231 cells. In each panel of Fig 3, FZD7 suppressed cells with FZD7shRNA transduction 
showed significant growth retardation (P<0.05). The data indicates that FZD7 plays a critical 
role in cell growth of TNBC. 
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Fig. 3. FZD7 regulated cell growth in MDA-MB-231 cells. 
2.2.2 FZD7 plays an important role in cell motility and invasion 
We have noted that FZD7 enhances cell growth in TNBC. We then asked whether FZD7 is 
involved in cell motility and invasion of TNBC. We evaluated the invasive ability of the cells 
with or without FZD7 by using an invasion assay. MDA-MB-231 and BT-20 cells that 
express GFPshRNA actively migrated into the bottom layer of the membrane of the insert 
chamber after overnight culture. A representative area from each well for each cell line 
cultured was analyzed. The number of invasive cells in the membrane was quantified using 
the Image-Pro 6.3 software. As shown in Fig. 4A, MDA-MB-231 and BT20 cells treated with  
 
 
 
Fig. 4. FZD7 increased cell migration in TNBC. 
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GFPshRNA virus showed aggressive migration from the metrigel to the membrane. The 
numbers of cells in the membrane of MDA-MB-231/GFPshRNA and BT-20/GFPshRNA 
cells were 2.6 and 1.9 times higher than those of MDA-MB-231/FZD7shRNA and BT-
20/FZD7shRNA cells respectively. To address the effect of FZD7 in cell motility, we 
performed a wound healing assay. MDA-MB-231/GFPshRNA cells migrated to the wound 
area within 16 hours and completely closed the wound within 24 hours; whereas with FZD7 
inhibited cells, the wound remained open even after 24 hours of observation (Fig. 4B).  
These results suggested that FZD7 exert positive effect on cell migration in TNBC. 
2.2.3 FZD7 modulated cell tumorigenicity in TNBC 
It has been shown that FZD7 is involved in not only enhanced cell growth, but also 
enhanced cell migration, raising the possibility that FZD7 might be a regulator for cell 
tumorigenicity in TNBC. To verify this hypothesis, colony formation assay was performed 
on both FZD7 expressing and FZD7 suppressed MDA-MB-231 cells. It was found that more 
than twice the number of colonies was observed in GPFshRNA expressing cells as compared 
to MDA-MB-231/FZD7shRNA cells (Fig. 5). These results indicated that FZD7 is a key 
factor involved cell colonigenicity in TNBC. Increased colonigenicity in TNBC cells 
expressing FZD7 lead to accelerated tumor growth in TNBC. 
 
 
Fig. 5. FZD7 increased cell tumorigenicity in TNBC. 
2.3 FZD7 regulated cell transformation through cannonical Wnt signaling pathway 
FZD7 is known as the receptor for the Wnt signaling pathway. To investigate if FZD7 affects 
TNBC tumor cell biology through the canonical Wnt pathway, β-catenin 
immunofluorescence and DAPI staining was performed to determine the localization of β-
catenin thereby confirming the involvement of the Wnt/β-catenin pathway. β-catenin 
accumulated in the nuclei of MDA-MB-231 cells transduced with GFPshRNA (Figure 5A). 
However, in cells in which FZD7 expression was suppressed by FZD7shRNA, β-catenin 
staining was attenuated in the nuclei and remained in the cytoplasm. Furthermore, 
assessment of TCF7 promoter activity by dual luciferase assay revealed that the promoter 
activity of TCF7 declined by approximately 50% in FZD7 inhibited MDA-MB-231 and BT-20 
cells (Figure 5B).  
We then assessed whether expression of target genes of the Wnt pathway (e.g., Cyclin D1 
and C-myc) changed when FZD7 was inhibited. Western blot analysis revealed decreased 
expression of Cyclin D1 and C-myc, downstream components of the Wnt pathway, in MDA-
MB-231 and BT-20 cells in which FZD7 was knocked down as compared to GFPshRNA-
expressing control cells (Figure5C). To evaluate whether overexpression of FZD7 was 
sufficient to trigger Wnt/β-catenin signaling, FZD7 tagged with GFP was transiently 
expressed in MCF7 cells, which expresses low levels of FZD7. MDA-MB-231 cells served as 
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control. Approximately 70% to 80% of transfected cells were GFP-positive, indicating that 
FZD7 should have been overexpressed. However, overexpression of FZD7 did not activate 
the Wnt canonical pathway (Figure 5D), and did not appear to generate a significant cell 
proliferation benefit (Figure 5E).  
 
 
Fig. 6. FZD7 regulated cell transformation through Wnt canonical pathway in TNBC. 
In our microarray data, we noticed that two genes, FZD and PKCB1, along the noncanonical 
Wnt/Ca2+ pathway were upregulated in TNBC. In the Wnt/Ca2+ pathway, Wnt binds to 
FZD to initiate signaling that results in the stimulation of protein kinase C (PKC) and the 
release of intracellular Ca2+. Increased concentrations of Ca2+ induce dephosphorylation of 
NFAT (nuclear factor of activated T-cells), which promotes its translocation to the nucleus 
where it can activate the transcription of target genes of the Wnt/Ca2+ pathway. However, 
when FZD7 was inhibited in MDA-MB-231 and BT-20 cells, expression of PKCB1 and the 
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phosphorylation status of NFAT did not change (Figure 7), suggesting that FZD7 does not 
have a role in Wnt/Ca2+ signaling in TNBC. Taken together, these data provide strong 
evidence that Wnt/β-catenin, but not Wnt/Ca2+ signaling is active in TNBC, and that 
blocking the Wnt canonical pathway leads to tumor cells losing their tumorigenicity.  
 
 
Fig. 7. FZD7 knockdown suppressed tumor growth in vivo. 
2.4 FZD7shRNA suppresses tumor growth in vivo 
To explore whether the Wnt pathway contributes to the tumorigenesis of TNBC in vivo, 
MDA-MB-231 cells with FZD7shRNA or GFPshRNA were inoculated into NOD-SCID IL2rg 
female null mice. FZD7shRNA blocked the Wnt signal in MDA-MB-231 cells and induced 
significant (p<0.001) suppression of tumor growth in vivo. Moreover, growth arrest has 
been observed in MDA-MB-231/FZD7shRNA cell-derived tumors after 1 week of inoculation 
(Fig. 6A). Gross tissue was harvested and processed with immunohistochemistry (IHC) 
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staining of Wnt pathway gene FZD7, β-catenin, and Wnt pathway target gene Cyclin D1 
(Fig. 6B). In Fig. 5B left panel, the GFPshRNA control group tumor showed normal FZD7 
expression, β-catenin locatization in the nucleus, and Cyclin D1 expression. In tumors with 
FZD7shRNA shown in the right panel, most cells expressed β-catenin in the cytoplasm and 
did not express Cyclin D1. This result is consistent with the in vitro findings and confirms 
that FZD7shRNA induces growth retardation via the Wnt canonical signal. Furthermore, the 
tumors with FZD7 or FZD7 suppression were characterized. Hypoxia cell marker CA9, 
angiogenesis marker CD31 and cell proliferation marker Ki67 in the cells were stained (Fig. 
6B). The data revealed that Ki67 expression was significantly increased in FZD7 expressed 
tumor but not in FZD7 inhibited tumor. CA9 was weakly expressed in both FZD7 expressed 
tumor and FZD7 suppressed tumor. CD31 was not detected in either tumor. These findings 
indicate that the activation of Wnt signal in TNBC induces cell proliferation, but may not 
directly involve cell hypoxia and angiogenesis.  
3. Conclusion 
TNBC has been a particular focus of attention because it has no confirmed therapeutic 
molecular target and poor prognosis. Basal-like breast cancer is categorized as TNBC 
because almost all basal-like breast cancers have no hormone receptor expression and HER2 
overexpression (Perou et al., 2000; Sotiriou et al., 2003). Although aberrant Wnt signaling 
activation has been observed in breast cancer (Brown, 2001; Turashvili et al., 2006), the 
correlation of Wnt signaling with TNBC has rarely been investigated. However, canonical 
Wnt pathway activation in basal-like tumor has been observed (DiMeo et al., 2009; Lindvall 
et al., 2009). More recently, LRP6 overexpression was found in a subtype of breast tumor that 
is ER-negative and Her2-negative (Liu et al., 2010). This is consistent with our microarray 
results. In our study, downregulation of FZD7 to inactivate the Wnt signaling in triple 
negative breast cell line, MDA-MB-231 and BT-20 resulted in impaired cell growth and 
tumor transformation. The essential role that canonical Wnt signaling plays in TNBC makes 
it the most attractive therapeutic stratagem in TNBC (Yang et al., 2011). Targeting Wnt 
pathway genes as novel pharmacological agent for other neoplasms has been investigated 
and great effect has been observed (Yang et al., 2008). Wnt pathway receptor FZD7 and 
LRP6 are cell surface antigens. Our data together with other recent findings suggest that 
with the inhibition of either of these two genes, Wnt signaling pathway will be blocked and 
Wnt signal-mediated cell proliferation will be suppressed (Bafico et al., 2001). SiRNA or 
antibodies against these mRNAs or proteins will provide strong blocking of canonical Wnt 
signaling in TNBC cells. Small molecules that inhibit the biological functions of these two 
genes may also be powerful drugs for treatment of TNBC. Notably, any agents that increase 
the phosphorylation activity of CK1 and GSK3 or block β-catenin nuclear accumulation will 
be possible therapeutic approaches for TNBC.  
Constitutive expression of Wnt signaling enhances the self-renewal of mammary progenitor 
cells, and continuous stimulation of this pathway leads to the formation of breast tumor 
(Jones and Kemp, 2008; Lindvall et al., 2007). Mouse model study indicated that breast 
cancers that arise from stem-progenitor cells undergo transformation through deregulation 
of the Wnt signal, while epithelial cell derived breast tumors are triggered by oncogenic 
activation of HER2 (Li and Rosen, 2005). We also noticed that breast cell lines expressing 
high levels of HER2 usually express low levels of FZD7 (data not shown). The association of 
Wnt signaling and HER2 in breast tumor development will be further explored.  
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Wnt signaling pathway is a highly conserved pathway. Three signaling branches have been 
identified: canonical Wnt pathway (Wnt/β-catenin pathway), non-canonical pathway 
(including planar cell polarity pathway), and Wnt/Ca2+ pathway (Komiya and Habas, 2008). 
We have observed that two genes, FDZ and PKC, along the Wnt/Ca2+ pathway were 
upregulated in TNBC. Addressing the significance of this branch in TNBC in the future 
remains important. 
 
 
Fig. 8. FZD7 as a target for TNBC. 
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